MUC1 peptide 619

MUC1 peptide 619 is a therapeutic cancer vaccine candidate consisting of a specific peptide fragment derived from the Mucin 1 (MUC1) protein. MUC1 is a transmembrane glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial cancers, including pancreatic, breast, and lung cancers, making it a significant tumor-associated antigen. The vaccine is designed to stimulate the patient's immune system, specifically inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. By presenting the MUC1 peptide in conjunction with HLA molecules (typically HLA-A*0201 or HLA-A*2402), the vaccine aims to promote the recognition and lysis of malignant cells. Clinical development has primarily focused on its application in advanced pancreatic cancer, often as part of a dendritic cell-based vaccine or in combination with adjuvants to enhance immunogenicity.

Other names

MUC1 peptideMUC-1 peptideMUC 1 peptideMUC1-619MUC-1-619MUC 1-619